2000 – 2008 Journal articles

2019 | 20182017 | 2016 | 2015 | 20142013 | 2012 | 2011 | 2010 | 2009 | 2000-2008 | Publications

[31]White, P. J.; Anastasopoulos, F.; Church, J. E.; Kuo, C. Y.; Boyd, B. J.; Hickey, P. L. C.; Tu, L. S.; Burns, P.; Lew, A. M.; Heath, W. R.; Davey, G. M.; Pouton, C. W., Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants. Vaccine 2008, 26 (52), 6824-6831.
[30]Kaminskas, L. M.; Boyd, B. J.; Karellas, P.; Krippner, G. Y.; Lessene, R.; Kelly, B.; Porter, C. J. H., The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers. Molecular Pharmaceutics 2008, 5 (3), 449-463.
[29]Dong, Y. D.; Dong, A. W.; Larson, I.; Rappolt, M.; Amenitsch, H.; Hanley, T.; Boyd, B. J., Impurities in commercial phytantriol significantly alter its lyotropic liquid-crystalline phase behavior. Langmuir 2008, 24 (13), 6998-7003.
[28]Boyd, B. J., Past and future evolution in colloidal drug delivery systems. Expert Opinion on Drug Delivery 2008, 5 (1), 69-85.
[27]Rizwan, S. B.; Dong, Y. D.; Boyd, B. J.; Rades, T.; Hook, S., Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo FESEM). Micron 2007, 38 (5), 478-485.
[26]Kaminskas, L. M.; Boyd, B. J.; Karellas, P.; Henderson, S. A.; Giannis, M. P.; Krippner, G. Y.; Porter, C. J. H., Impact of surface derivatization of poly-L-lysine dendrimers with anionic aryisulfonate or succinate groups on intravenous pharmacokinetics and disposition. Molecular Pharmaceutics 2007, 4 (6), 949-961.
[25]Boyd, B. J.; Rizwan, S. B.; Dong, Y.-D.; Hook, S.; Rades, T., Self-assembled geometric liquid-crystalline nanoparticles imaged in three dimensions: Hexosomes are not necessarily flat hexagonal prisms. Langmuir 2007, 23 (25), 12461-12464.
[24]Boyd, B. J.; Khoo, S.-M.; Whittaker, D. V.; Davey, G.; Porter, C. J. H., A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. International journal of pharmaceutics 2007, 340 (1-2), 52-60.
[23]Sek, L.; Boyd, B. J.; Charman, W. N.; Porter, C. J. H., Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipiclic formulations of atovaquone. Journal of Pharmacy and Pharmacology 2006, 58 (6), 809-820.
[22]Ma, J.-G.; Boyd, B. J.; Drummond, C. J., Positional isomers of linear sodium dodecyl benzene sulfonate: Solubility, self-assembly, and air/water interfacial activity. Langmuir 2006, 22 (21), 8646-8654.
[21]Dong, Y.-D.; Larson, I.; Hanley, T.; Boyd, B. J., Bulk and dispersed aqueous phase behavior of phytantriol: Effect of vitamin E acetate and F127 polymer on liquid crystal nanostructure. Langmuir 2006, 22 (23), 9512-9518.
[20]Boyd, B. J.; Whittaker, D. V.; Khoo, S.-M.; Davey, G., Hexosomes formed from glycerate surfactants - Formulation as a colloidal carrier for irinotecan. International journal of pharmaceutics 2006, 318 (1-2), 154-162.
[19]Boyd, B. J.; Whittaker, D. V.; Khoo, S. M.; Davey, G., Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. International journal of pharmaceutics 2006, 309 (1-2), 218-226.
[18]Boyd, B. J.; Kaminskas, L. M.; Karellas, P.; Krippner, G.; Lessene, R.; Porter, C. J. H., Cationic poly-L-lysine dendrimers: Pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Molecular Pharmaceutics 2006, 3 (5), 614-627.
[17]Kossena, G. A.; Charman, W. N.; Boyd, B. J.; Porter, C. I. H., Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. Journal of pharmaceutical sciences 2005, 94 (3), 481-492.
[16]Fong, C.; Krodkiewska, I.; Wells, D.; Boyd, B. J.; Booth, J.; Bhargava, S.; McDowall, A.; Hartley, P. G., Submicron dispersions of hexosomes based on novel glycerate surfactants. Australian Journal of Chemistry 2005, 58 (9), 683-687.
[15]Boyd, B. J., Controlled release from cubic liquid-crystalline particles (cubosomes). In Bicontinuous Liquid Crystals , Spicer, P. T., Ed. 2005; Vol. 127, pp 285-305.
[14]Porter, C. J. H.; Kaukonen, A. M.; Taillardat-Bertschinger, A.; Boyd, B. J.; O'Connor, J. M.; Edwards, G. A.; Charman, W. N., Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine. Journal of pharmaceutical sciences 2004, 93 (5), 1110-1121.
[13]Porter, C. J. H.; Kaukonen, A. M.; Boyd, B. J.; Edwards, G. A.; Charman, W. N., Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharmaceutical Research 2004, 21 (8), 1405-1412.
[12]Kossena, G. A.; Charman, W. N.; Boyd, B. J.; Porter, C. J. H., A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs. Journal of Controlled Release 2004, 99 (2), 217-229.
[11]Kossena, G. A.; Charman, W. N.; Boyd, B. J.; Dunstan, D. E.; Porter, C. J. H., Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: A phase diagram approach. Journal of pharmaceutical sciences 2004, 93 (2), 332-348.
[10]Kaukonen, A. M.; Boyd, B. J.; Porter, C. J. H.; Charman, W. N., Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharmaceutical Research 2004, 21 (2), 245-253.
[9]Kaukonen, A. M.; Boyd, B. J.; Charman, W. N.; Porter, C. J. H., Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. Pharmaceutical Research 2004, 21 (2), 254-260.
[8]Kossena, G. A.; Boyd, B. J.; Porter, C. J. H.; Charman, W. N., Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. Journal of pharmaceutical sciences 2003, 92 (3), 634-648.
[7]Drummond, C. J.; Fong, C.; Krodkiewska, I.; Boyd, B. J.; Baker, I. J. A., Sugar Fatty Acid Esters. In Novel Surfactants: Preparation, Applications and Biodegradability , Holmberg, K., Ed. Marcel Dekker: New York, 2003.
[6]Boyd, B. J.; Porter, C. J. H.; Charman, W. N., Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products. Journal of pharmaceutical sciences 2003, 92 (6), 1262-1271.
[5]Boyd, B. J., Characterisation of drug release from cubosomes using the pressure ultrafiltration method. International journal of pharmaceutics 2003, 260 (2), 239-247.
[4]Boyd, B. J.; Krodkiewska, I.; Drummond, C. J.; Grieser, F., Chiral glucose-derived surfactants: The effect of stereochemistry on thermotropic and lyotropic phase behavior. Langmuir 2002, 18 (3), 597-601.
[3]Boyd, B. J.; Drummond, C. J.; Krodkiewska, I.; Weerawardena, A.; Furlong, D. N.; Grieser, F., Alkyl chain positional isomers of dodecyl beta-D-glucoside: Thermotropic and lyotropic phase behavior and detergency. Langmuir 2001, 17 (20), 6100-6107.
[2]Weerawardena, A.; Boyd, B. J.; Drummond, C. J.; Furlong, D. N., Removal of a solid organic soil from a hard surface by glucose-derived surfactants: effect of surfactant chain length, headgroup polymerisation and anomeric configuration. Colloids and Surfaces A-Physicochemical and Engineering Aspects 2000, 169 (1-3), 317-328.
[1]Boyd, B. J.; Drummond, C. J.; Krodkiewska, I.; Grieser, F., How chain length, headgroup polymerization, and anomeric configuration govern the thermotropic and lyotropic liquid crystalline phase behavior and the air-water interfacial adsorption of glucose-based surfactants. Langmuir 2000, 16 (19), 7359-7367.

2019 | 20182017 | 2016 | 2015 | 20142013 | 2012 | 2011 | 2010 | 2009 | 2000-2008 | Publications